Kelley CF, Acevedo-Quiñones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, Brinson C, Brites C, Cahn P, Cantos VD, Clark J, Clement M, Creticos C, Crofoot G, Diaz RS, Doblecki-Lewis S, Gallardo-Cartagena JA, Gaur A, Grinsztejn B, Hassler S, Hinojosa JC, Hodge T, Kaplan R, Lacerda M, LaMarca A, Losso MH, Valdez Madruga J, Mayer KH, Mills A, Mounzer K, Ndlovu N, Novak RM, Perez Rios A, Phanuphak N, Ramgopal M, Ruane PJ, Sánchez J, Santos B, Schine P, Schreibman T, Spencer LY, Van Gerwen OT, Vasconcelos R, Vasquez JG, Zwane Z, Cox S, Deaton C, Ebrahimi R, Wong P, Singh R, Brown LB, Carter CC, Das M, Baeten JM, Ogbuagu O; PURPOSE 2 Study Team. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. N Engl J Med. 2025 Apr 3;392(13):1261-1276. doi: 10.1056/NEJMoa2411858. Epub 2024 Nov 27. PMID: 39602624.

Papot E, Tovar-Sanchez T, Woods J, Thaurignac G, Eriobu N, Borok M, Kaplan R, Avihingsanon A, Azwa I, Grinsztejng B, Kumarasamy N, Sokhela S, Mpoudi-Etame M, Arriaga M, Jacoby S, Matthews GV, Losso MH, Khoo S, Calmy A, Kouanfack C, Ayouba A, Petoumenos K, Venter WDF, Delaporte E, Polizzotto MN; COHIVE study group. SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa. AIDS. 2025 Mar 15;39(4):448-456.

Nyein PP, Borok M, Eriobu N, Kaplan R, Kumarasamy N, Avihingsanon A, Losso MH, Azwa I, Karyana M, Dao S, Cisse M, Villanueva JFA, Lupo S, Cardoso SW, Yunihastuti E, Subronto YW, Fitriah M, Katu S, Brown D, Papot E, Hutchinson J, Kelleher A, Hanson J, Dharan NJ, Petoumenos K, Matthews GV; DEFT Study Team. A randomised trial to compare dolutegravir plus boosted darunavir versus recommended standard of care antiretroviral regimens in people with HIV-1, whose first-line non-nucleoside reverse transcriptase inhibitor therapy has failed: Final 96-week results of the D2EFT study. Clin Infect Dis. 2025 Jun 27:ciaf346. doi: 10.1093/cid/ciaf346. Epub ahead of print. PMID: 40577173.

Havens JP, Kang N, Chung L, Fletcher CV, Crew P, Nordwall J, Siegel L, Harper K, Grund B, Losso M, Vasudeva S, Molina KC, Ginde AA, Shimizu R, Mourad A, Diallo A, Pak M, Davis-Karim A, Nabaggala P, Mena Lora AJ, Russell DW, Saito S, Baker JV. Implementation of an Online Drug-Drug Interaction Screener for the STRIVE Ensitrelvir Trial for COVID-19. Open Forum Infect Dis. 2025 Jun 11;12(7):ofaf327. doi: 10.1093/ofid/ofaf327. PMID: 40599489; PMCID: PMC12207740.

Luedtke A, Fong Y, van der Laan L, Heng F, Huang Y, Lu Y, Yu C, Carpp LN, Roels S, Le Gars M, Van Roey GA, Stieh DJ, Van Dromme I, Kenny A, Carone M, Losso MH, Little SJ, Gaur A, Swann E, Petropoulos CJ, McDermott AB, Sadoff J, Gray GE, Grinsztejn B, Goepfert PA, Follmann D, Roychoudhury P, Greninger AL, Koup RA, Donis RO, Gilbert PB; Immune Assays Team; Coronavirus Vaccine Prevention Network (CoVPN)/ENSEMBLE Team; United States Government (USG)/CoVPN Biostatistics Team. Immune correlates analysis of antibody responses against SARS-CoV-2 variants in the ENSEMBLE vaccine efficacy trial. iScience. 2025 Sep 29;28(11):113660. doi: 10.1016/j.isci.2025.113660. PMID: 41210956; PMCID: PMC12589887.

Buchbinder SP, Spinosa Guzman S, Sanchez J, Willems W, Stieh DJ, van Duijn J, van Rosmalen MGM, Hendriks J, Nijs S, Lavreys L, Paez CA, Grinzstejn B, Hutter J, Mann P, Sierra Madero JG, Cahn P, Castagna A, Truyers C, Roels S, Gilbert PB, Carone M, Luedtke A, Corey L, Pau MG, Tomaka F; HVTN 706/HPX3002/Mosaico Study Team. Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet HIV. 2025 Dec;12(12):e823-e835. doi: 10.1016/S2352-3018(25)00195-X. PMID: 41314741.

Tusch E, Ryom L, Pelchen-Matthews A, Mocroft A, Elbirt D, Oprea C, Günthard HF, Staehelin C, Zangerle R, Suarez I, Vehreschild JJ, Wit F, Menozzi M, d’Arminio Monforte A, Spagnuolo V, Pradier C, Carlander C, Suanzes P, Wasmuth JC, Carr A, Petoumenos K, Borgans F, Bonnet F, De Wit S, El-Sadr W, Neesgaard B, Jaschinski N, Greenberg L, Hosein SR, Gallant J, Vannappagari V, Young L, Sabin C, Lundgren J, Peters L, Reekie J; D:A:D cohort study; RESPOND cohort study. Trends in Mortality in People With HIV From 1999 through 2020: A Multicohort Collaboration. Clin Infect Dis. 2024 Nov 22;79(5):1242-1257. doi: 10.1093/cid/ciae228. PMID: 38663013; PMCID: PMC11581700.

Aggarwal NR, Nordwall J, Braun DL, Chung L, Coslet J, Der T, Eriobu N, Ginde AA, Hayanga AJ, Highbarger H, Holodniy M, Horcajada JP, Jain MK, Kim K, Laverdure S, Lundgren J, Natarajan V, Nguyen HH, Pett SL, Phillips A, Poulakou G, Price DA, Robinson P, Rogers AJ, Sandkovsky U, Shaw-Saliba K, Sturek JM, Trautner BW, Waters M, Reilly C; ACTIV-3/TICO Study Group. Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19. Clin Infect Dis. 2024 Jun 14;78(6):1490-1503. doi: 10.1093/cid/ciad780. PMID: 38376212; PMCID: PMC11175705.

D2EFT Study Group. Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D$^{2}$EFT): an open-label, randomised, phase 3b/4 trial. Lancet HIV. 2024 Jul;11(7):e436-e448. doi: 10.1016/S2352-3018(24)00089-4. Epub 2024 May 21. PMID: 38788744; PMCID: PMC11700562.

Jensen TO, Grandits GA, Jain MK, Murray TA, Grund B, Shaw-Saliba K, Matthay MA, Abassi M, Ardelt M, Baker JV, Chen P, Dewar RL, Goodman AL, Hatlen TJ, ACTIV-3/TICO Study Group. Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19. J Infect Dis. 2024 Mar 14;229(3):671-679. doi: 10.1093/infdis/jiad446. PMID: 37948759; PMCID: PMC10938202.

Jensen TO, Murray TA, Grandits GA, Jain MK, Grund B, Shaw-Saliba K, Matthay MA, Abassi M, Ardelt M, Baker JV, Chen P, Dewar RL, Goodman AL, Hatlen TJ, Highbarger HC, Holodniy M, Lallemand P, Laverdure S, Leshnower BG, Looney D, Moschopoulos CD, Mugerwa H, Murray DD, Mylonakis E, Nagy-Agren S, Rehman MT, Rupert A, Stevens R, Turville S, Weintrob A, Wick K, Lundgren J, Ko ER; ACTIV-3/TICO Study Group. Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study. Lancet Microbe. 2024 Jun;5(6):e559-e569. doi: 10.1016/S2666-5247(24)00015-6. Epub 2024 May 27. PMID: 38815595; PMCID: PMC11181148.

Magaret CA, Li L, deCamp AC, Rolland M, Juraska M, Williamson BD, Ludwig J, Molitor C, Benkeser D, Luedtke A, Simpkins B, Heng F, Sun Y, Carpp LN, Bai H, Dearlove BL, Giorgi EE, Jongeneelen M, Brandenburg B, McCallum M, Bowen JE, Veesler D, Sadoff J, Gray GE, Roels S, Vandebosch A, Stieh DJ, Le Gars M, Vingerhoets J, Grinsztejn B, Goepfert PA, de Sousa LP, Silva MST, Casapia M, Losso MH, Little SJ, Gaur A, Bekker LG, Garrett N, Truyers C, Van Dromme I, Swann E, Marovich MA, Follmann D, Neuzil KM, Corey L, Greninger AL, Roychoudhury P, Hyrien O, Gilbert PB. Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features. Nat Commun. 2024 Mar 11;15(1):2175. doi: 10.1038/s41467-024-46536-w. PMID: 38467646; PMCID: PMC10928100.

Balevic SJ, Benjamin DK Jr, Powderly WG, Smith PB, Gonzalez D, McCarthy MW, Shaw LK, Lindsell CJ, Bozzette S, Williams D, Linas BP, Blamoun J, Javeri H, Hornik CP; ACTIV-1 IM Study Group. Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19: A Secondary Analysis of the ACTIV-1 IM Randomized Clinical Trial. JAMA Netw Open. 2024 Apr 1;7(4):e247615. doi: 10.1001/jamanetworkopen.2024.7615. PMID: 38662372; PMCID: PMC11046337.

Clement ME, Hanscom B, Haines D, Bazan JA, Chotirosniramit N, Kofron R, Mannheimer S, Mayer KH, Torres Silva MS, Soto-Torres L, Rinehart AR, Rooney JF, Jennings A, Gomez-Feliciano K, McCauley M, Grinsztejn B, Landovitz RJ; for HPTN 083 Study Team. Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083. Clin Infect Dis. 2024 Nov 23:ciae572. doi: 10.1093/cid/ciae572. Epub ahead of print. PMID: 39579334.

Bullo M, Kierszenowicz T, Acosta MC, Rolon MJ, Cecchini D, Rodriguez C, Scapellato P, Bottaro E, Losso MH. Telemedicine in HIV health care during the COVID-19 pandemic: An implementation research study in Buenos Aires, Argentina. HIV Med. 2024 Aug;25(8):927-934. doi: 10.1111/hiv.13646. Epub 2024 Apr 24. PMID: 38657752.

Clement ME, Hanscom B, Haines D, Bazan JA, Chotirosniramit N, Kofron R, Mannheimer S, Mayer KH, Torres Silva MS, Soto-Torres L, Rinehart AR, Rooney JF, Jennings A, Gomez-Feliciano K, McCauley M, Grinsztejn B, Landovitz RJ; for HPTN 083 Study Team. Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083. Clin Infect Dis. 2024 Nov 23:ciae572. doi: 10.1093/cid/ciae572. Epub ahead of print. PMID: 39579334.

Kelley CF, Acevedo-Quiñones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, Brinson C, Brites C, Cahn P, Cantos VD, Clark J, Clement M, Creticos C, Crofoot G, Diaz RS, Doblecki-Lewis S, Gallardo-Cartagena JA, Gaur A, Grinsztejn B, Hassler S, Hinojosa JC, Hodge T, Kaplan R, Lacerda M, LaMarca A, Losso MH, Valdez Madruga J, Mayer KH, Mills A, Mounzer K, Ndlovu N, Novak RM, Perez Rios A, Phanuphak N, Ramgopal M, Ruane PJ, Sánchez J, Santos B, Schine P, Schreibman T, Spencer LY, Van Gerwen OT, Vasconcelos R, Vasquez JG, Zwane Z, Cox S, Deaton C, Ebrahimi R, Wong P, Singh R, Brown LB, Carter CC, Das M, Baeten JM, Ogbuagu O; PURPOSE 2 Study Team. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. N Engl J Med. 2025 Apr 3;392(13):1261-1276. doi: 10.1056/NEJMoa2411858. Epub 2024 Nov 27. PMID: 39602624.

Magaret C, Li L, deCamp A, Rolland M, Juraska M, Williamson B, Ludwig J, Molitor C, Benkeser D, Luedtke A, Simpkins B, Carpp L, Bai H, Dearlove B, Greninger A, Roychoudhury P, Sadoff J, Gray G, Roels S, Vandebosch A, Stieh D, Gars ML, Vingerhoets J, Grinsztejn B, Goepfert P, Truyers C, Dromme IV, Swann E, Marovich M, Follmann D, Neuzil K, Corey L, Hyrien O, de Sousa LP, Casapia M, Losso M, Little S, Gaur A, Bekker LG, Garrett N, Heng F, Sun Y, Gilbert P. Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features. Res Sq [Preprint]. 2023 May 31:rs.3.rs-2743022. doi: 10.21203/rs.3.rs-2743022/v1.

Lundgren JD, Babiker AG, Sharma S, Grund B, Phillips AN, Matthews G, Kan VL, Aagaard B, Abo I, Alston B, Arenas-Pinto A, Avihingsanon A, Badal-Faesen S, Brites C, Carey C, Casseb J, Clarke A, Collins S, Corbelli GM, Dao S, Denning ET, Emery S, Eriobu N, Florence E, Furrer H, Fätkenheuer G, Gerstoft J, Gisslén M, Goodall K, Henry K, Horban A, Hoy J, Hudson F, Azwa RISR, Kedem E, Kelleher A, Kityo C, Klingman K, Rosa A, Leturque N, Lifson AR, Losso M, Lutaakome J, Madero JS, Mallon P, Mansinho K, Filali KME, Molina JM, Murray DD, Nagalingeswaran K, Nozza S, Ormaasen V, Paredes R, Peireira LC, Pillay S, Polizzotto MN, Raben D, Rieger A, Sanchez A, Schechter M, Sedlacek D, Staub T, Touloumi G, Turner M, Madruga JV, Vjecha M, Wolff M, Wood R, Zilmer K, Lane HC, Neaton JD; INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group. Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection. NEJM Evid. 2023 Mar;2(3):10.1056/evidoa2200302. doi: 10.1056/evidoa2200302.

Mena Lora AJ, Long JE, Huang Y, Baden LR, El Sahly HM, Follmann D, Goepfert P, Gray G, Grinsztejn B, Kotloff K, Rouphael N, Sobieszczyk M, Walsh SR, Andriesen J, Shah KA, Zhang Y, Gilbert P, Janes H, Gay CL, Falsey AR, Tripp RL, Gorman RL, Tong T, Losso M, Marovich M, Neuzil K, Corey L, Kublin JG; COVID-19 Prevention Network. Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. JAMA Netw Open. 2023 Jan 3;6(1):e2251974. doi: 10.1001/jamanetworkopen.2022.51974. Erratum in: JAMA Netw Open. 2023 May 1;6(5):e2317317. PMID: 36689221.

Kundro MA, Losso MH, Macchia A, Pastor I, Alonso Serena M, Gestoso C, Moreno Macías L, Crupi F, Acosta MC, Ivalo S, Ghioldi M, Bouzas MB, Mammana L, Zapiola I, Mazzitelli I, Varese A, Geffner J, Biscayart C, Angeleri P, Lopez E, Gentile A, Ferrante D, de Quiros FGB. Safety and immunogenicity of heterologous COVID-19 vaccine regimens to deal with product shortage: A randomised clinical trial in an elderly population. Public Health Pract (Oxf). 2022 Dec;4:100313. doi: 10.1016/j.puhip.2022.100313. Epub 2022 Sep 6.

Gabrielaite M, Bennedbæk M, Rasmussen MS, Kan V, Furrer H, Flisiak R, Losso M, Lundgren JD; INSIGHT START Study Group; Marvig RL. Deep-sequencing of viral genomes from a large and diverse cohort of treatment-naive HIV-infected persons shows associations between intrahost genetic diversity and viral load. PLoS Comput Biol. 2023 Jan 3;19(1):e1010756.

Marzinke MA, Hanscom B, Wang Z, Safren SA, Psaros C, Donnell D, Richardson PA, Sullivan P, Eshleman SH, Jennings A, Feliciano KG, Jalil E, Coutinho C, Cardozo N, Maia B, Khan T, Singh Y, Middelkoop K, Franks J, Valencia J, Sanchez N, Lucas J, Rooney JF, Rinehart AR, Ford S, Adeyeye A, Cohen MS, McCauley M, Landovitz RJ, Grinsztejn B; HPTN 083 study group. Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial. Lancet HIV. 2023 Nov;10(11):e703-e712. doi: 10.1016/S2352-3018(23)00200-X. Epub 2023 Sep 29. PMID: 37783219; PMCID: PMC10842527.

O’Halloran JA, Ko ER, Anstrom KJ, Kedar E, McCarthy MW, Panettieri RA Jr, Maillo M, Nunez PS, Lachiewicz AM, Gonzalez C, Smith PB, de Tai SM, Khan A, Lora AJM, Salathe M, Capo G, Gonzalez DR, Patterson TF, Palma C, Ariza H, Lima MP, Blamoun J, Nannini EC, Sprinz E, Mykietiuk A, Alicic R, Rauseo AM, Wolfe CR, Witting B, Wang JP, Parra-Rodriguez L, Der T, Willsey K, Wen J, Silverstein A, O’Brien SM, Al-Khalidi HR, Maldonado MA, Melsheimer R, Ferguson WG, McNulty SE, Zakroysky P, Halabi S, Benjamin DK Jr, Butler S, Atkinson JC, Adam SJ, Chang S, LaVange L, Proschan M, Bozzette SA, Powderly WG; ACTIV-1 IM Study Group Members. Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA. 2023 Jul 25;330(4):328-339. doi: 10.1001/jama.2023.11043. PMID: 37428480; PMCID: PMC10334296.

Béguelin C, Atkinson A, Boyd A, Falconer K, Kirkby N, Suter-Riniker F, Günthard HF, Rockstroh JK, Mocroft A, Rauch A, Peters L, Wandeler G; for EuroSIDA and SHCS. Hepatitis delta infection among persons living with HIV in Europe. Liver Int. 2023 Apr;43(4):819-828. doi: 10.1111/liv.15519. Epub 2023 Jan 21. PMID: 36625770.

Lundgren JD, Babiker AG, Sharma S, Grund B, Phillips AN, Matthews G, Kan VL, Aagaard B, Abo I, Alston B, Arenas-Pinto A, Avihingsanon A, Badal-Faesen S, Brites C, Carey C, Casseb J, Clarke A, Collins S, Corbelli GM, Dao S, Denning ET, Emery S, Eriobu N, Florence E, Furrer H, Fätkenheuer G, Gerstoft J, Gisslén M, Goodall K, Henry K, Horban A, Hoy J, Hudson F, Azwa RISR, Kedem E, Kelleher A, Kityo C, Klingman K, Rosa A, Leturque N, Lifson AR, Losso M, Lutaakome J, Madero JS, Mallon P, Mansinho K, Filali KME, Molina JM, Murray DD, Nagalingeswaran K, Nozza S, Ormaasen V, Paredes R, Peireira LC, Pillay S, Polizzotto MN, Raben D, Rieger A, Sanchez A, Schechter M, Sedlacek D, Staub T, Touloumi G, Turner M, Madruga JV, Vjecha M, Wolff M, Wood R, Zilmer K, Lane HC, Neaton JD; INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group. Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection. NEJM Evid. 2023 Mar;2(3):10.1056/evidoa2200302. doi: 10.1056/evidoa2200302. Epub 2023 Feb 27. PMID: 37213438; PMCID: PMC10194271.

Mena Lora AJ, Long JE, Huang Y, Baden LR, El Sahly HM, Follmann D, Goepfert P, Gray G, Grinsztejn B, Kotloff K, Rouphael N, Sobieszczyk M, Walsh SR, Andriesen J, Shah KA, Zhang Y, Gilbert P, Janes H, Gay CL, Falsey AR, Tripp RL, Gorman RL, Tong T, Marovich M, Neuzil K, Corey L, Kublin JG; COVID-19 Prevention Network. Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. JAMA Netw Open. 2023 Jan 3;6(1):e2251974. doi: 10.1001/jamanetworkopen.2022.51974. Erratum in: JAMA Netw Open. 2023 May 1;6(5):e2317317. doi: 10.1001/jamanetworkopen.2023.17317. PMID: 36689221; PMCID:PMC10546713.

Surial B, Ramírez Mena A, Roumet M, Limacher A, Smit C, Leleux O, Mocroft A, van der Valk M, Bonnet F, Peters L, Rockstroh JK, Günthard HF, Berzigotti A, Rauch A, Wandeler G; Swiss HIV Cohort Study; ATHENA Observational Cohort Study; EuroSIDA; ANRS CO3 Aquitaine Cohort. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection. J Hepatol. 2023 May;78(5):947-957. doi: 10.1016/j.jhep.2022.12.029. Epub 2023 Jan 21. PMID: 36690280.

ACTIV-3/TICO Study Group, Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial. Ann Intern Med. 2022 Sep;175(9):1266-1274. doi: 10.7326/M22-1503. Epub 2022 Aug 9. PMID: 35939810; PMCID: PMC9384272.

Kundro MA, Losso MH, Macchia A, Pastor I, Alonso Serena M, Gestoso C, Moreno Macías L, Crupi F, Acosta MC, Ivalo S, Ghioldi M, Bouzas MB, Mammana L, Zapiola I, Mazzitelli I, Varese A, Geffner J, Biscayart C, Angeleri P, Lopez E, Gentile A, Ferrante D, de Quiros FGB. Safety and immunogenicity of heterologous COVID-19 vaccine regimens to deal with product shortage: A randomised clinical trial in an elderly population. Public Health Pract (Oxf). 2022 Dec;4:100313. doi: 10.1016/j.puhip.2022.100313. Epub 2022 Sep 6. PMID: 36090797; PMCID: PMC9444309.

Mocroft A, Miro JM, Wandeler G, Llibre JM, Boyd A, van Bremen K, Beniowski M, Mikhalik J, Cavassini M, Maltez F, Duvivier C, Uberti Foppa C, Knysz B, Bakowska E, Kuzovatova E, Domingo P, Zagalo A, Viard JP, Degen O, Milinkovic A, Benfield T, Peters L; EuroSIDA study group. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study. HIV Med. 2022 Jul;23(6):585-598. doi: 10.1111/hiv.13210. Epub 2021 Dec 9. PMID: 34889022.

Papot E, Jacoby S, Arlinda D, Avihingsanon A, Azwa I, Borok M, Brown D, Cissé M, Dao S, Eriobu N, Kaplan R, Karyana M, Kumarasamy N, Lee J, Losso MH, Matthews GV, Perelis L, Perez-Casas C, Ruxrungtham K, Watkins M, Lane HC, Kelleher A, Law M, Polizzotto MN; D2EFT Study Group. Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D2EFT. HIV Res Clin Pract. 2022 Jul 19;23(1):37-46. PMID: 35938597.

ACTIV-3/TICO Study Group, Rogers AJ, Wentworth D, Phillips A, Shaw-Saliba K, Dewar RL, Aggarwal NR, Babiker AG, Chang W, Dharan NJ, Davey VJ, Higgs ES, Gerry N, Ginde AA, Hayanga JWA, Highbarger H, Highbarger JL, Jain MK, Kan V, Kim K, Lallemand P, Leshnower BG, Lutaakome JK, Matthews G, Mourad A, Mylonakis E, Natarajan V, Padilla ML, Pandit LM, Paredes R, Pett S, Ramachandruni S, Rehman MT, Sherman BT, Files DC, Brown SM, Matthay MA, Thompson BT, Neaton JD, Lane HC, Lundgren JD. The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19. Ann Intern Med. 2022 Oct;175(10):1401-1410. doi: 10.7326/M22-0924. Epub 2022 Aug 30. PMID: 36037469; PMCID: PMC9447373.

Pastor I, Kundro MA, Viloria GA, Losso MH. Viruela símica: descripción de dos casos en seguimiento en Buenos Aires [Monkeypox: description of two cases under follow-up in Buenos Aires]. Medicina (B Aires). 2022;82(5):774-776.

162. Cozzi-Lepri A, Peters L, Pelchen-Matthews A, Neesgaard B, De Wit S, Johansen IS, Edwards S, Stephan C, Adamis G, Staub T, Zagalo A, Domingo P, Elbirt D, Kusejko K, Brännström J, Paduta D, Trofimova T, Szlavik J, Zilmer K, Losso M, Van Eygen V, Pai H, Lundgren J, Mocroft A; EuroSIDA Study Group. Observational cohort study of rilpivirine (RPV) utilization in Europe. AIDS Res Ther. 2022 Aug 6;19(1):38. doi: 10.1186/s12981-022-00457-0.

Bentzon AK, Panteleev A, Mitsura V, Borodulina E, Skrahina A, Denisova E, Tetradov S, Podlasin R, Riekstina V, Kancauskiene Z, Paduto D, Mocroft A, Trofimova T, Miller R, Post F, Grezesczuk A, Lundgren JD, Inglot M, Podlekareva D, Bolokadze N, Kirk O; TB:HIV Study Group. Healthcare delivery for HIV-positive people with tuberculosis in Europe. HIV Med. 2021 Apr;22(4):283-293. doi: 10.1111/hiv.13016. Epub 2020 Nov 20. PMID: 33215809.

Kowalska JD, Pelchen-Matthews A, Ryom L, Losso MH, Trofimova T, Mitsura VM, Khromova I, Paduta D, Stephan C, Domingo P, Bakowska E, Monforte AD, Oestergaard L, Jablonowska E, Kuznetsova A, Moreno S, Vasylyev M, Pradier C, Battegay M, Vandekerckhove L, Castagna A, Raben D, Mocroft A; EuroSIDA Study Group. Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. AIDS. 2021 Oct 1;35(12):2025-2033. doi: 10.1097/QAD.0000000000002954. PMID: 34033590.

Henry RT, Jiamsakul A, Law M, Losso M, Kamarulzaman A, Phanuphak P, Kumarasamy N, Foulkes S, Mohapi L, Nwizu C, Wood R, Kelleher A, Polizzotto M; SECOND-LINE Study Group. Factors Associated With and Characteristic of HIV/Tuberculosis Co-Infection: A Retrospective Analysis of SECOND-LINE Clinical Trial Participants. J Acquir Immune Defic Syndr. 2021 May 1;87(1):720-729. doi: 10.1097/QAI.0000000000002619. PMID: 33399309.

149: Amele S, Sandri AK, Rodger A, Vandekerckhove L, Benfield T, Milinkovic A, Duvivier C, Stellbrink HJ, Sambatakou H, Chkhartishvili N, Caldeira L, Laguno M, Domingo P, Wandeler G, Gisinger M, Kuzovatova E, Dragovic G, Knysz B, Matulionyte R, Rockstroh JK, Lundgren JD, Mocroft A, Peters L; EuroSIDA study group. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe. HIV Med. 2022 Jul;23(6):684-692. doi: 10.1111/hiv.13212. Epub 2021 Dec 9. PMID: 34882940.

150: Pelchen-Matthews A, Larsen JF, Shepherd L, Begovac J, Pedersen K, De Wit S, Horban A, Jablonowska E, Johnson M, Khromova I, Losso MH, Nielsen LN, Ridolfo AL, Schmied B, Stephan C, Yust I, Curtis L, Vannappagari V, Ragone L, Roen A, Raben D, Kirk O, Peters L, Mocroft A; EuroSIDA Study Group. Hypersensitivity reactions, hepatotoxicity, and other discontinuations in persons receiving integrase strand transfer inhibitors: results from the EuroSIDA study. HIV Res Clin Pract. 2021 Dec;22(6):160-168. Epub 2021 Nov 15. PMID: 34779362.

151: Roen AO, Podlekareva D, Miller RF, Mocroft A, Panteleev A, Skrahina A, Miro JM, Cayla JA, Tetradov S, Derisova E, Furrer H, Losso MH, Vassilenko A, Girardi E, Lundgren JD, Post FA, Kirk O. A new health care index predicts short term mortality for TB and HIV co-infected people. Int J Tuberc Lung Dis. 2020 Sep 1;24(9):956-962. doi: 10.5588/ijtld.19.0568. PMID: 33156764.

152: Beigel JH, Manosuthi W, Beeler J, Bao Y, Hoppers M, Ruxrungtham K, Beasley RL, Ison M, Avihingsanon A, Losso MH, Langlois N, Hoopes J, Lane HC, Holley HP, Myers CA, Hughes MD, Davey RT. Effect of Oral Oseltamivir on Virological Outcomes in Low-risk Adults With Influenza: A Randomized Clinical Trial. Clin Infect Dis. 2020 May 23;70(11):2317-2324. doi: 10.1093/cid/ciz634. PMID: 31541242; PMCID: PMC7245154.

153: Kraef C, Bentzon A, Panteleev A, Skrahina A, Bolokadze N, Tetradov S, Podlasin R, Karpov I, Borodulina E, Denisova E, Azina I, Lundgren J, Johansen IS, Mocroft A, Podlekareva D, Kirk O; T. B.:H. I. V. Study Group. Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality-a multicentre prospective cohort study. BMC Infect Dis. 2021 Oct 6;21(1):1038. doi: 10.1186/s12879-021-06745-w. PMID: 34615474; PMCID: PMC8496077.

Davey RT Jr, Fernández-Cruz E, Markowitz N, Pett S, Babiker AG, Wentworth D, Khurana S, Engen N, Gordin F, Jain MK, Kan V, Polizzotto MN, Riska P, Ruxrungtham K, Temesgen Z, Lundgren J, Beigel JH, Lane HC, Neaton JD; INSIGHT FLU-IVIG Study Group. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. Lancet Respir Med. 2019 Nov;7(11):951-963. doi: 2 10.1016/S2213-2600(19)30253-X. Epub 2019 Sep 30. PubMed PMID: 31582358; PubMed Central PMCID: PMC6868512.

Laut K, Kirk O, Rockstroh J, Phillips A, Ledergerber B, Gatell J, Gazzard B, Horban A, Karpov I, Losso M, d’Arminio Monforte A, Pedersen C, Ristola M, Reiss P, Scherrer AU, de Wit S, Aho I, Rasmussen LD, Svedhem V, Wandeler G, Pradier C, Chkhartishvili N, Matulionyte R, Oprea C, Kowalska JD, Begovac J, Miró JM, Guaraldi G, Paredes R, Raben D, Podlekareva D, Peters L, Lundgren JD, Mocroft A. The EuroSIDA study: 25 years of scientific achievements. HIV Med. 2020 Feb;21(2):71-83. doi: 10.1111/hiv.12810. Epub 2019 Oct 24. PMID: 31647187.

WHO Solidarity Trial Consortium, Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results. N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2. PMID: 33264556; PMCID: PMC7727327.

Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, Offergeld K, Scheper G, Taylor KL, Robb ML, Treanor J, Barouch DH, Stoddard J, Ryser MF, Marovich MA, Neuzil KM, Corey L, Cauwenberghs N, Tanner T, Hardt K, Ruiz-Guiñazú J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Douoguih M; ENSEMBLE Study Group. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021 Jun 10;384(23):2187-2201. doi: 10.1056/NEJMoa2101544. Epub 2021 Apr 21. PMID: 33882225; PMCID: PMC8220996.

Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, Cabello R, Chariyalertsak S, Dunne EF, Frank I, Gallardo-Cartagena JA, Gaur AH, Gonzales P, Tran HV, Hinojosa JC, Kallas EG, Kelley CF, Losso MH, Madruga JV, Middelkoop K, Phanuphak N, Santos B, Sued O, Valencia Huamaní J, Overton ET, Swaminathan S, Del Rio C, Gulick RM, Richardson P, Sullivan P, Piwowar-Manning E, Marzinke M, Hendrix C, Li M, Wang Z, Marrazzo J, Daar E, Asmelash A, Brown TT, Anderson P, Eshleman SH, Bryan M, Blanchette C, Lucas J, Psaros C, Safren S, Sugarman J, Scott H, Eron JJ, Fields SD, Sista ND, Gomez-Feliciano K, Jennings A, Kofron RM, Holtz TH, Shin K, Rooney JF, Smith KY, Spreen W, Margolis D, Rinehart A, Adeyeye A, Cohen MS, McCauley M, Grinsztejn B; HPTN 083 Study Team. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021 Aug 12;385(7):595-608. doi: 10.1056/NEJMoa2101016. PMID: 34379922; PMCID: PMC8448593.

Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, Savoy N, Giunta DH, Pérez LG, Sánchez MDL, Gamarnik AV, Ojeda DS, Santoro DM, Camino PJ, Antelo S, Rainero K, Vidiella GP, Miyazaki EA, Cornistein W, Trabadelo OA, Ross FM, Spotti M, Funtowicz G, Scordo WE, Losso MH, Ferniot I, Pardo PE, Rodriguez E, Rucci P, Pasquali J, Fuentes NA, Esperatti M, Speroni GA, Nannini EC, Matteaccio A, Michelangelo HG, Follmann D, Lane HC, Belloso WH; PlasmAr Study Group. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med. 2021 Feb 18;384(7):619-629. doi: 10.1056/NEJMoa2031304. Epub 2020 Nov 24. PMID: 33232588; PMCID: PMC7722692.

Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Van Dromme I, Spiessens B, Vingerhoets J, Custers J, Scheper G, Robb ML, Treanor J, Ryser MF, Barouch DH, Swann E, Marovich MA, Neuzil KM, Corey L, Stoddard J, Hardt K, Ruiz-Guiñazú J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Douoguih M; ENSEMBLE Study Group. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. N Engl J Med. 2022 Mar 3;386(9):847-860. doi: 10.1056/NEJMoa2117608. Epub 2022 Feb 9. PMID: 35139271; PMCID: PMC8849184.

ITAC (INSIGHT 013) Study Group. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. Lancet. 2022 Feb 5;399(10324):530-540. doi: 10.1016/S0140-6736(22)00101-5. Epub 2022 Jan 28. PMID: 35093205; PMCID: PMC8797010.

Laut K, Kirk O, Rockstroh J, Phillips A, Ledergerber B, Gatell J, Gazzard B, Horban A, Karpov I, Losso M, d’Arminio Monforte A, Pedersen C, Ristola M, Reiss P, Scherrer AU, de Wit S, Aho I, Rasmussen LD, Svedhem V, Wandeler G, Pradier C, Chkhartishvili N, Matulionyte R, Oprea C, Kowalska JD, Begovac J, Miró JM, Guaraldi G, Paredes R, Raben D, Podlekareva D, Peters L, Lundgren JD, Mocroft A. The EuroSIDA study: 25 years of scientific achievements. HIV Med. 2020 Feb;21(2):71-83. doi: 10.1111/hiv.12810. Epub 2019 Oct 24. PMID: 31647187.

Eke AC, Wang J, Amin K, Shapiro DE, Stek A, Smith E, Chakhtoura N, Basar M, George K, Knapp KM, João EC, Rungruengthanakit K, Capparelli E, Burchett S, Mirochnick M, Best BM; P1026s Protocol Team. Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy. Antimicrob Agents Chemother. 2020 Mar 24;64(4):e02260-19. doi: 10.1128/AAC.02260-19. PMID: 32015036; PMCID: PMC7179299.

Mocroft A, Lundgren JD, Rockstroh JK, Aho I, Wandeler G, Nielsen L, Edwards S, Viard JP, Lacombe K, Fätkenheuer G, Guaraldi G, Laguno M, Llibre J, Elinav H, Flamholc L, Gisinger M, Paduta D, Khromova I, Jilich D, Rozplochowski B, Oprea C, Peters L; EuroSIDA study. Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons. Open Forum Infect Dis. 2020 Oct 7;7(12):ofaa470. doi: 10.1093/ofid/ofaa470. PMID: 33409325; PMCID: PMC7772946.

Mocroft A, Lundgren J, Gerstoft J, Rasmussen LD, Bhagani S, Aho I, Pradier C, Bogner JR, Mussini C, Uberti Foppa C, Maltez F, Laguno M, Wandeler G, Falconer K, Trofimova T, Borodulina E, Jevtovic D, Bakowska E, Kase K, Kyselyova G, Haubrich R, Rockstroh JK, Peters L; EuroSIDA Study. Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment. Clin Infect Dis. 2020 May 6;70(10):2131-2140. doi: 10.1093/cid/ciz601. PMID: 31504296.

Hoffman RM, Brummel SS, Britto P, Pilotto JH, Masheto G, Aurpibul L, Joao E, Purswani MU, Buschur S, Pierre MF, Coletti A, Chakhtoura N, Klingman KL, Currier JS; PROMISE (Promoting Maternal and Infant Safety Everywhere) 1077HS Team. Adverse Pregnancy Outcomes Among Women Who Conceive on Antiretroviral Therapy. Clin Infect Dis. 2019 Jan 7;68(2):273-279.

Ekenberg C, Tang ME, Zucco AG, Murray DD, MacPherson CR, Hu X, Sherman BT, Losso MH, Wood R, Paredes R, Molina JM, Helleberg M, Jina N, Kityo CM, Florence E, Polizzotto MN, Neaton JD, Lane HC, Lundgren JD; INSIGHT START Study Group. Single nucleotide polymorphisms in HLA alleles are associated with HIV-1 viral load in demographically diverse, ART-naïve participants from the START trial. J Infect Dis. 2019

Amele S, Peters L, Sluzhynska M, Yakovlev A, Scherrer A, Domingo P, Gerstoft J, Viard JP, Gisinger M, Flisiak R, Bhaghani S, Ristola M, Leen C, Jablonowska E, Wandeler G, Stellbrink H, Falconer K, D’Arminio Monforte A, Horban A, Rockstroh JK, Lundgren JD, Mocroft A; EuroSIDA study group. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA. HIV Med. 2019 Apr;20(4):264-273

Aboud M, Kaplan R, Lombaard J, Zhang F, Hidalgo JA, Mamedova E, Losso MH, Chetchotisakd P, Brites C, Sievers J, Brown D, Hopking J, Underwood M, Nascimento MC, Punekar Y, Gartland M, Smith K. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis. 2019 Mar;19(3):253-264.

Beigel JH, Manosuthi W, Beeler J, Bao Y, Hoppers M, Ruxrungtham K, Beasley RL, Ison M, Avihingsanon A, Losso MH, Langlois N, Hoopes J, Lane HC, Holley HP, Myers CA, Hughes MD, Davey RT. Effect of Oral Oseltamivir on Virological Outcomes in Low-risk Adults With Influenza: A Randomized Clinical Trial. Clin Infect Dis. 2020 May 23;70(11):2317-2324. doi: 10.1093/cid/ciz634. PMID: 31541242; PMCID: PMC7245154.

Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Madero JS, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Alberto Arnaiz J, Cooper D, Rockstroh JK, Mallon P, Emery S; MARCH study group. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study. HIV Med. 2018 Jan;19(1):65-71.

Acosta MC, Kundro M, Viloria G, Peressín Paz A, Morello F, Latorre F, Seoane E, Toibaro J, Losso M. The role of brain biopsy in the clinical management of HIV-related focal brain lesions. HIV Med. 2018 Nov;19(10):673-678.

Laut K, Shepherd L, Radoi R, Karpov I, Parczewski M, Mussini C, Maltez F, Losso M, Chkhartishvili N, Elinav H, Kovari H, Blaxhult A, Zangerle R, Trofimova T, Inglot M, Zilmer K, Kuzovatova E, Staub T, Raben D, Lundgren J, Mocroft A, Kirk O, On Behalf Of The EuroSIDA Study Group. Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015. Euro Surveill. 2018 May;23(21).

Simonsen L, Higgs E, Taylor RJ, Wentworth D, Cozzi-Lepri A, Pett S, Dwyer DE, Davey R, Lynfield R, Losso M, Morales K, Glesby MJ, Weckx J, Carey D, Lane C, Lundgren J; INSIGHT FLU002 and FLU003 Study Groups. Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic. Clin Infect Dis. 2018 Jul 18;67(3):341-349.

Caro-Vega Y, Schultze A, W Efsen AM, Post FA, Panteleev A, Skrahin A, Miro JM, Girardi E, Podlekareva DN, Lundgren JD, Sierra-Madero J, Toibaro J, Andrade-Villanueva J, Tetradov S, Fehr J, Caylà J, Losso MH, Miller RF, Mocroft A, Kirk O, Crabtree-Ramírez B. Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America. BMC Infect Dis. 2018 Apr 23;18(1):191.

Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d’Arminio Monforte A, Kovari H, Law M, Lundgren JD, Sabin CA; Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group. Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study. J Int AIDS Soc. 2018 Mar;21(3).

Santos JR, Cozzi-Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A, Sluzhynska M, Orkin C, Duvivier C, Bogner J, Gargalianos-Kakolyris P, Schmid P, Hassoun G, Khromova I, Beniowski M, Hadziosmanovic V, Sedlacek D, Paredes R, Lundgren JD; EuroSIDA study group. Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe. HIV Med. 2018 May;19(5):324-338.

Molina JM, Grund B, Gordin F, Williams I, Schechter M, Losso M, Law M, Ekong E, Mwelase N, Skoutelis A, Wiselka MJ, Vandekerckhove L, Benfield T, Munroe D, Lundgren JD, Neaton JD; INSIGHT START study group. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial. Lancet HIV. 2018 Apr;5(4):e172-e180.

Mwasakifwa GE, Moore C, Carey D, Amin J, Penteado P, Losso M, Lim PL, Mohapi L, Molina JM, Gazzard B, Cooper DA, Boyd M; SECOND-LINE Study Group. Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy. AIDS. 2018 Jan 28;32(3):357-361.

Dwyer DE, Lynfield R, Losso MH, Davey RT, Cozzi-Lepri A, Wentworth D, Uyeki TM, Gordin F, Angus B, Qvist T, Emery S, Lundgren J, Neaton JD; INSIGHT Influenza Study Group. Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009-2015. Open Forum Infect Dis. 2017 Oct 7;4(4):ofx212.

Roen A, Laut K, Pelchen-Matthews A, Borodulina E, Caldeira L, Clarke A, Clotet B, d’Arminio Monforte A, Fätkenheuer G, Gatell Artigas JM, Karpov I, Kuznetsova A, Kyselyova G, Mozer-Lisewska I, Losso MH, Mulcahy F, Ragone L, Scherrer A, Uzdaviniene V, Vandekerckhove L, Vannappagari V, Ostergaard L, Mocroft A; EuroSIDA study. Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort. HIV Med. 2018 Apr;19(4):252-260.

Efsen AMW, Schultze A, Miller RF, Panteleev A, Skrahin A, Podlekareva DN, Miro JM, Girardi E, Furrer H, Losso MH, Toibaro J, Caylà JA, Mocroft A, Lundgren JD, Post FA, Kirk O; TB: HIV study in EuroCoord. Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study. J Infect. 2018 Jan;76(1):44-54.

Stankievich E, Malanca A, Foradori I, Ivalo S, Losso M. Utility of Mobile Communication Devices as a Tool to Improve Adherence to Antiretroviral Treatment in HIV-infected Children and Young Adults in Argentina. Pediatr Infect Dis J. 2018 Apr;37(4):345-348.

Cozzi-Lepri A, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H, Fätkenheuer G, Yust I, Schmid P, Gottfredsson M, Khromova I, Jilich D, Flisiak R, Smidt J, Rozentale B, Radoi R, Losso MH, Lundgren JD, Mocroft A; EuroSIDA Study Group. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. HIV Med. 2018 Feb;19(2):102-117.

Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Madero JS, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Alberto Arnaiz J, Cooper D, Rockstroh JK, Mallon P, Emery S; MARCH study group. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study. HIV Med. 2018 Jan;19(1):65-71.

Kundro MA, Viloria GA, Toibaro JJ, Losso MH. Antiretroviral therapy and arterial elasticity in HIV-infected patients. Medicina (B Aires). 2017;77(5):365-369. PubMed PMID: 29044011.

Stankievich E, Malanca A, Foradori I, Ivalo S, Losso M. Utility of Mobile Communication Devices as a Tool to Improve Adherence to Antiretroviral Treatment in HIV-Infected Children and Young Adults in Argentina. Pediatr Infect Dis J. 2017 Oct 7.

Cozzi-Lepri A, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H, Fätkenheuer G, Yust I, Schmid P, Gottfredsson M, Khromova I, Jilich D, Flisiak R, Smidt J, Rozentale B, Radoi R, Losso MH, Lundgren JD, Mocroft A; EuroSIDA Study Group. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. HIV Med. 2017 Oct 6.

Beigel JH, Bao Y, Beeler J, Manosuthi W, Slandzicki A, Dar SM, Panuto J, Beasley RL, Perez-Patrigeon S, Suwanpimolkul G, Losso MH, McClure N, Bozzolo DR, Myers C, Holley HP Jr, Hoopes J, Lane HC, Hughes MD, Davey RT; IRC003 Study Team. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. Lancet Infect Dis. 2017 Dec;17(12):1255-1265.

Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Madero JS, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Alberto Arnaiz J, Cooper D, Rockstroh JK, Mallon P, Emery S; MARCH study group. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study. HIV Med. 2018 Jan;19(1):65-71. Epub 2017 Jul 13.

Currier JS, Britto P, Hoffman RM, Brummel S, Masheto G, Joao E, Santos B, Aurpibul L, Losso M, Pierre MF, Weinberg A, Gnanashanmugam D, Chakhtoura N, Klingman K, Browning R, Coletti A, Mofenson L, Shapiro D, Pilotto J; 1077HS PROMISE Team. Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm3. PLoS One. 2017 May

Malanca A, Foradori I, Stankievich E, Pandullo H, Losso M. [Disclosure of human immunodeficiency virus diagnosis in children and adolescents affected by it and their caregivers]. Arch Argent Pediatr. 2017 Apr 1;115(2):195-199.

TB:HIV Study writing Group. One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid-susceptible tuberculosis in Eastern Europe, Western Europe, and Latin America. AIDS. 2017 Jan 28;31(3):375-384.

Pett SL, Kunisaki KM, Wenworth D, y col. Increased indoleamine 2-3 Dioxygenase activity is associated with poor clinical outcome in adults hospitalized with influenza in the INSIGHT FLU003Plus study. Open Forum Infect Dis 2017; Oct 25, 5(1)

Dwyer DE, Lynfield R, Losso MH, y col. Comparison of the outcomes of individuals with medically attended influenza A and B virus infections enrolled in 2 international cohort studies over a 6 year period: 2009-2015. Open Forum Infect Dis 2017; Oct 7;4(4)

Vazquez C, Orlova M, Angriman F, Minatta JN, Scibona P, Verzura MA, Jáuregui EG, Díaz de Arce H, Pallotta MG, Belloso WH. Prediction of severe toxicity in adult patients under treatment with 5-fluoruracil: a prospective cohort study. Anticancer Drugs 2017; Oct 28(9):1039-46.

Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Madero JS, Belloso WH, Tu E, Silk D, Kelleher A, y col. Week 96 results of the randomized multicentre Maraviroc Switch (MARCH) study. HIV Med 2017; Jul 13

Achhra AC, Mocroft A, Ross M, Ryom-Nyelson L, Avihingsanon A, Bakowska E, Belloso WH, Clarke A, Furrer H, Lucas GM, Ristola M, Rassool M, Ross J, y col. Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START Trial. Int J Antimicrob Agents 2017; Jun 28

Vazquez C, Orlova M, Scibona P, Diaz Arce H, Pallotta MG, Belloso WH. Prevalence of thymidylate synthase gene 5´untranslated region variants in an Argentinean sample. Gen Mol res 2017; 16(1)

Boyd MA, Amin J, Mallon PW, Kumarasamy N, Lombaard J, Wood R, Chetchotisakd P, Phanuphak P, Mohapi L, Azwa I, Belloso WH, Molina JM, Hoy J, Moore CL, Emery S, Cooper DA; SECOND-LINE Study Group. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. Lancet HIV. 2017 Jan;4(1):e13-e20.

Rodriguez Loria G, Losso MH, Mosqueda L, Viloria G, Alave J, Andrade Villanueva J, David D, Laplumé H, de Paz M, Lupo S, Michaans M, Belloso WH. Establishment of a prospective cohort of adult HIV positive patients in Latin America (LATINA Prospective Cohort).

Boyd MA, Amin J, Mallon PW, Kumarasamy N, Lombaard J, Wood R, Chetchotisakd P, Phanuphak P, Mohapi L, Azwa I, Belloso WH, Molina JM, Hoy J, Moore CL, Emery S, Cooper DA; SECOND-LINE Study Group. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. Lancet HIV. 2017 Jan;4(1):e13-e20. doi:

Musso CG, Belloso WH. Monitoring of kidney function in elderly HIV-positive patients. HIV Med. 2016 Jul 6. doi: 10.1111/hiv.12395.

Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Sierra Madero J, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Fisher M, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Arnaiz JA, Cooper D, Rockstroh JK, Mallon P, Emery S; Maraviroc Switch (MARCH) Study Group.. Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study. Clin Infect Dis. 2016 Jul 1;63(1):122-32

Alvarez E, Belloso WH. Boyd MA, Inkaya AC, Hsieh E, Kambugu A, Kaminski G, Martinez E, Stellbrink HJ, Walmsley S, Brown TT, Mallon PW, Which patients should be screened for osteoporosis: an international perspective. Curr Opin HIV AIDS 2016 Feb 18. Epub ahead of print.

Musso CG, Belloso WH. Glassock RJ. Water, electrolytes and acid-base alterations in human immunodeficiency virus infected patients. World J Nephrol 2016 Jan 6;5(1):33-42.

Baker JV, Hullsiek KH, Engen NW, Nelson R, Chetchotisakd P, Gerstoft J, JessenH, Losso M, Markowitz N, Munderi P, Papadopoulos A, Shuter J, Rappoport C,Pearson MT, Finley E, Babiker A, Emery S, Duprez D; INSIGHT START ArterialElasticity Substudy Team.. Early Antiretroviral Therapy at High CD4 Counts DoesNot Improve Arterial Elasticity: A Substudy of the Strategic Timing ofAntiRetroviral Treatment (START) Trial. Open Forum Infect Dis. 2016 Oct8;3(4):ofw213.

Llibre JM, Cozzi-Lepri A, Pedersen C, Ristola M, Losso M, Mocroft A, MitsuraV, Falconer K, Maltez F, Beniowski M, Vullo V, Hassoun G, Kuzovatova E, SzlavikJ, Kuznetsova A, Stellbrink HJ, Duvivier C, Edwards S, Laut K, Paredes R;EuroSIDA Study.. Long-term effectiveness of unboosted atazanavir plusabacavir/lamivudine in subjects with virological suppression: A prospectivecohort study. Medicine (Baltimore). 2016 Oct;95(40):e5020.

Kundro MA, Terwel SR, Toibaro JJ, Viloria GA, Losso MH. Late diagnosis of HIV infection in asymptomatic patients. Medicina (B Aires). 2016;76(5):273-278.

Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, SierraMadero J, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W,Wolff M, Gill J, Gatell J, Fisher M, Clarke A, Ruxrungtham K, Prazuck T, KaiserR, Woolley I, Arnaiz JA, Cooper D, Rockstroh JK, Mallon P, Emery S; MaravirocSwitch (MARCH) Study Group.. Maraviroc, as a Switch Option, in HIV-1-infectedIndividuals With Stable, Well-controlled HIV Replication and R5-tropic Virus onTheir First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor PlusRitonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study. Clin Infect Dis. 2016 Jul 1;63(1):122-32.

Podlekareva DN, Efsen AM, Schultze A, Post FA, Skrahina AM, Panteleev A,Furrer H, Miller RF, Losso MH, Toibaro J, Miro JM, Vassilenko A, Girardi E,Bruyand M, Obel N, Lundgren JD, Mocroft A, Kirk O; TB:HIV study group inEuroCoord.. Tuberculosis-related mortality in people living with HIV in Europeand Latin America: an international cohort study. Lancet HIV. 2016Mar;3(3):e120-31.

Efsen AM, Schultze A, Post FA, Panteleev A, Furrer H, Miller RF, Losso MH,Toibaro J, Skrahin A, Miro JM, Caylà JA, Girardi E, Bruyand M, Obel N,Podlekareva DN, Lundgren JD, Mocroft A, Kirk O; TB:HIV study group in EuroCoord..Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America. PLoS One. 2015 Dec30;10(12):e0145380.

Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, OrrellC, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R.Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at96 Weeks: Results of the ENCORE1 Study. Clin Pharmacokinet. 2016Jul;55(7):861-73.

Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. Boyd MA, Moore CL, Molina JM, Wood R, Madero JS, Wolff M, Ruxrungtham K, Losso M, Renjifo B, Teppler H, Kelleher AD, Amin J, Emery S, Cooper DA; SECOND-LINE study group. Lancet HIV. 2015 Feb;2(2):e42-51. doi: 10.1016/S2352-3018(14)00061-7

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816.

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study. Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, Orrell C, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R; ENCORE1 Study Group. Clin Pharmacol Ther. 2015 Oct;98(4):406-16. doi: 10.1002/cpt.156.

INVESTIGATING THE EFFICACY OF CLINICAL TRIAL MONITORING STRATEGIES: Design and Implementation of the Cluster Randomized START Monitoring Substudy. Hullsiek KH, Kagan JM, Engen N, Grarup J, Hudson F, Denning ET, Carey C, Courtney-Rodgers D, Finley EB, Jansson PO, Pearson MT, Peavy DE, Belloso WH. Ther Innov Regul Sci. 2015 Mar 1;49(2):225-233.

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. ENCORE1 Study Group, Carey D, Puls R, Amin J, Losso M, Phanupak P, Foulkes S, Mohapi L, Crabtree-Ramirez B, Jessen H, Kumar S, Winston A, Lee MP, Belloso W, Cooper DA, Emery S. Lancet Infect Dis. 2015 Jul;15(7):793-802. doi: 10.1016/S1473-3099(15)70060-5.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. PLoS Med. 2015 Mar 31;12(3):e1001809.

Clinical outcomes of first-line antiretroviral therapy in Latin America: analysis from the LATINA retrospective cohort study. Angriman F, Belloso WH, Sierra-Madero J, Sánchez J, Moreira RI, Kovalevski LO, Orellana LC, Cardoso SW, Crabtree-Ramirez B, La Rosa A, Losso MH. Int J STD AIDS. 2016 Feb;27(2):118-26.

Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cART. Winston A, Puls R, Kerr SJ, Duncombe C, Li P, Gill JM, Ramautarsing R, Taylor-Robinson SD, Emery S, Cooper DA; ALTAIR Study Group. PLoS One. 2015 Feb 27;10(2):e0118608.

Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. HIV Med. 2015 Apr;16 Suppl 1:1-9. doi: 10.1111/hiv.12227.

Angriman F, Belloso WH, Sierra Madero J, Sanchez J, Moreira RI, Kovalevski LO, Orellana LC, Cardoso SW, Crabtree Ramirez B, La Rosa A, Losso MH. Clinical Outcomes of first line antiretroviral therapy in Latin America: analysis from the LATINA retrospective cohort study. Int J STD AIDS 2015, Mar 3.

Huppler Hulsiek K, Kagan JM, Engen N, Grarup J, Hudson F, Denning ET, Carey C, Courtney-Rodgers D, Finley EB, Jansson PO, Pearson MT, Peavy DE, Belloso WH. Investigating the efficacy of clinical trial monitoring strategies: design and implementation of the cluster randomized Start monitoring substudy. Ther Innov Reg Sci, 2014: 1-9

Haskelberg H, Mallon PW, Hoy J, Amin J, Moore C, Phanuphak P, Ferret S, Belloso WH, Boyd MA, Cooper DA, Emery S. Bone mineral density over 96 weeks in adults failing first-line therapy randomised to raltegravir/lopinavir/ritonavir compared to standard second-line therapy. J Acquir Immune Defic Syndr. 2014 Jul 25.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc. 2014 May 28;3(3):e000844.

Borges AH, O’Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee. Factors associated with D-dimer levels in HIV-infected individuals. PLoS One. 2014 Mar 13;9(3):e90978.

ENCORE1 Study Group, Puls R, Amin J, Losso M, Phanuphak P, Nwizu C, Orrell C, Young B, Shahar E, Wolff M, Gazzard B, Read T, Hill A, Cooper DA, Emery S Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet. 2014 Apr 26;383(9927):1474-82

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.SECOND-LINE Study Group, Boyd MA, Kumarasamy N, Moore CL, Nwizu C, Losso MH, Mohapi L, Martin A, Kerr S, Sohn AH, Teppler H, Van de Steen O, Molina JM, Emery S, Cooper DA. Lancet. 2013 Jun 15;381(9883):2091-9.

Short and long term mortality and causes of death in HIV/TB patients in Europe.
Podlekareva DN, Panteleev AM, Grint D, Post FA, Miro JM, Bruyand M, Furrer H, Obel N, Girardi E, Vasilenko A, Losso MH, Arenas-Pinto A, Caylá J, Rakhmanova A, Zeltina I, Werlinrud AM, Lundgren JD, Mocroft A, Kirk O; the HIV/TB study group. Eur Respir J. 2013 Jun 13.

CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use.Mocroft A, Phillips AN, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Podlekareva D, Lundgren JD; EuroSIDA study in EuroCOORD. AIDS. 2013 Mar 27;27(6):907-18.

Sequence analysis of in vivo defective interfering-like RNA of influenza A H1N1 pandemic virus.Saira K, Lin X, DePasse JV, Halpin R, Twaddle A, Stockwell T, Angus B, Cozzi-Lepri A, Delfino M, Dugan V, Dwyer DE, Freiberg M, Horban A, Losso M, Lynfield R, Wentworth DN, Holmes EC, Davey R, Wentworth DE, Ghedin E; INSIGHT FLU002 Study Group; INSIGHT FLU003 Study Group. J Virol. 2013 Jul;87(14):8064-74.

Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study.Tu E, Swenson LC, Land S, Pett S, Emery S, Marks K, Kelleher AD, Kaye S, Kaiser R, Schuelter E, Harrigan R; MARCH Laboratory Group and the MARCH Study Group. J Clin Microbiol. 2013 Jul;51(7):2063-71.

Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?Rockstroh JK, Peters L, Grint D, Soriano V, Reiss P, Monforte Ad, Beniowski M, Losso MH, Kirk O, Kupfer B, Mocroft A; EuroSIDA in EuroCoord. J Hepatol. 2013 Aug;59(2):213-20.

Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy.Grint D, Peters L, Reekie J, Soriano V, Kirk O, Knysz B, Suetnov O, Lazzarin A, Ledergerber B, Rockstroh JK, Mocroft A; EuroSIDA in EuroCoord (European Coordinating Committee for the Integration of Ongoing Coordination Actions Related to Clinical and Epidemiological HIV Research). HIV Med. 2013 Jul;14(6):370-8.

Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, van ‘t Wout AB, Lubomirov R, Colombo S, Martinez R, Rauch A, Günthard HF, Neuhaus J, Wentworth D, van Manen D, Gras LA, Schuitemaker H, Albini L, Torti C, Jacobson LP, Li X, Kingsley LA, Carli F, Guaraldi G, Ford ES, Sereti I, Hadigan C, Martinez E, Arnedo M, Egaña-Gorroño L, Gatell JM, Law M, Bendall C, Petoumenos K, Rockstroh J, Wasmuth JC, Kabamba K, Delforge M, De Wit S, Berger F, Mauss S, de Paz Sierra M, Losso M, Belloso WH, Leyes M, Campins A, Mondi A, De Luca A, Bernardino I, Barriuso-Iglesias M, Torrecilla-Rodriguez A, Gonzalez-Garcia J, Arribas JR, Fanti I, Gel S, Puig J, Negredo E, Gutierrez M, Domingo P, Fischer J, Fätkenheuer G, Alonso-Villaverde C, Macken A, Woo J, McGinty T, Mallon P, Mangili A, Skinner S, Wanke CA, Reiss P, Weber R, Bucher HC, Fellay J, Telenti A, Tarr PE; MAGNIFICENT Consortium; INSIGHT; Swiss HIV Cohort Study. Clin Infect Dis. 2013 Jul;57(1):112-21.

The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies.Davey RT Jr, Lynfield R, Dwyer DE, Losso MH, Cozzi-Lepri A, Wentworth D, Lane HC, Dewar R, Rupert A, Metcalf JA, Pett SL, Uyeki TM, Bruguera JM, Angus B, Cummins N, Lundgren J, Neaton JD; INSIGHT FLU 002 & 003 Study Groups. PLoS One. 2013;8(2):e57121.

Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group. PLoS One. 2013;8(2):e56249.

Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; D:A:D Study Group. J Infect Dis. 2013 May 1;207(9):1359-69.

Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients.Podlekareva DN, Grint D, Post FA, Mocroft A, Panteleev AM, Miller RF, Miro JM, Bruyand M, Furrer H, Riekstina V, Girardi E, Losso MH, Caylá JA, Malashenkov EA, Obel N, Skrahina AM, Lundgren JD, Kirk O; HIV-TB Study Group.
Int J Tuberc Lung Dis. 2013 Feb;17(2):198-206.  

Platelet count kinetics following interruption of antiretroviral treatment.Zetterberg E, Neuhaus J, Baker JV, Somboonwit C, Llibre JM, Palfreeman A, Chini M, Lundgren JD; INSIGHT SMART Study Group. AIDS. 2013 Jan 2;27(1):59-68.

Martin A, Moore C, Mallon PW, Hoy J, Emery S, Belloso WH y col. HIV lipodystrophy in participants randomised to Lopinavir/ritonavir (LPV/r) +2-3 Nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line antiretroviral therapy. PloS One 2013; 8(10):e77138.

Martin A, Moore C, Mallon PW, Hoy J, Emery S, Belloso W y col. Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard Second Line therapy. AIDS 2013, Aug 6 [epub ahead of print]

SECOND-LINE Study Group, Boyd MA, Kumarasamy N, Moore CL, Nwizu C, Losso MH, Mohapi L, Martin A, Kerr S, Sohn AH, Teppler H, Van de Steen O, Molina JM, Emery S, Cooper DA. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet. 2013 Jun 15;381(9883):2091-9.

Bierk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group. Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study. PloS One 2013;8(2):e56249.

Zetterberg E, Neuhaus J, Baker JV, Somboonwit C, Llibre JM, Palfreeman A, Chini M, Lundgren JD; INSIGHT SMART Study Group. Platelet count kinetics following interruption of antiretroviral treatment. AIDS 2013 Juan 2;27(1):59-68.

Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D’Arminio Monforte A, Vehreschild JJ, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC). Int J Epidemiol. 2012 Dec;41(6):1807-20.

Long-term effects of intermittent IL-2 in HIV infection: extended follow-up of the INSIGHT STALWART Study.Markowitz N, Lopardo G, Wentworth D, Gey D, Babiker A, Fox L, Tavel J; STALWART Study Group. PLoS One. 2012;7(10):e47506.

Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Møller N, Lundgren JD, Law MG; D:A:D Study Group. J Int AIDS Soc. 2012 Oct 10;15(2):17426.

The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression.Mocroft A, Bannister WP, Kirk O, Kowalska JD, Reiss P, D’Arminio-Monforte A, Gatell J, Fisher M, Trocha H, Rakhmanova A, Lundgren JD; EuroSIDA Study in EuroCOORD. Antivir Ther. 2012;17(7):1291-300.

Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study. Podlekareva DN, Reekie J, Mocroft A, Losso M, Rakhmanova AG, Bakowska E, Karpov IA, Lazarus JV, Gatell J, Lundgren JD, Kirk O; EuroSIDA study in EuroCoord. BMC Infect Dis. 2012 Sep 25;12:229.

Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study. Reekie J, Kowalska JD, Karpov I, Rockstroh J, Karlsson A, Rakhmanova A, Horban A, Kirk O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord. PLoS One. 2012;7(7):e41673

Missed opportunities for prevention of mother-to-child transmission of HIV-1 in the NISDI Perinatal and LILAC cohorts.Read JS, Cohen RA, Hance LF, Machado ES, Mussi-Pinhata MM, Ceriotto M, Santos B, Succi R, Pilotto JH, Alarcon JO, Kreitchmann R; NISDI Perinatal/LILAC Study Group. Int J Gynaecol Obstet. 2012 Oct;119(1):70-5. Epub 2012 Jul 21.

Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients.Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, Reiss P, Grzeszczuk A, Sambatakou H, Mocroft A, Kirk O; EuroSIDA in EuroCoord. AIDS. 2012 Sep 24;26(15):1917-26.

Antiretroviral adherence during pregnancy and postpartum in Latin America.Kreitchmann R, Harris DR, Kakehasi F, Haberer JE, Cahn P, Losso M, Teles E, Pilotto JH, Hofer CB, Read JS; NISDI LILAC Study Team. AIDS Patient Care STDS. 2012 Aug;26(8):486-95.

Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, d’Arminio Monforte A, Phillips A, Lundgren JD, Kirk O; EuroSIDA study group. AIDS. 2012 Jan 28;26(3):315-23.

The NICHD International Site Development Initiative perinatal cohorts (2002-09). Read JS, Duarte G, Hance LF, Pinto J, Gouvea MI, Cohen RA, Santos B, Teles E, Succi R, Alarcon J, Stoszek SK; NISDI Perinatal Study Group. Int J Epidemiol. 2012 Jun;41(3):642-9.
Duprez, DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon D, Paton NI, Prineas RJ, Neaton JD; INSIGHT SMART Study Group. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One. 2012;7(9):e44454. doi: 10.1371/journal.pone.0044454. Epub 2012 Sep 10.

Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata.Reekie J, Gatell JM, Yust I, Bakowska E, Rakhmanova A, Losso M, Krasnov M, Francioli P, Kowalska JD, Mocroft A; EuroSIDA in EuroCoord. AIDS. 2011 Nov 28;25(18):2259-68.

Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site network approach: the INSIGHT FLU 002 and FLU 003 studies.Dwyer DE; INSIGHT Influenza Study Group. Vaccine. 2011 Jul 22;29 Suppl 2:B56-62.

Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors.Kruk A, Bannister W, Podlekareva DN, Chentsova NP, Rakhmanova AG, Horban A, Domingo P, Mocroft A, Lundgren JD, Kirk O; EuroSIDA study group. AIDS. 2011 Jul 31;25(12):1505-13.

Mode of delivery and neonatal respiratory morbidity among HIV-exposed newborns in Latin America and the Caribbean: NISDI Perinatal-LILAC Studies.Kreitchmann R, Cohen RA, Stoszek SK, Pinto JA, Losso M, Pierre R, Alarcon J, Succi R, Szyld E, Abreu T, Read JS. Int J Gynaecol Obstet. 2011 Aug;114(2):91-6.

Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study.Viard JP, Souberbielle JC, Kirk O, Reekie J, Knysz B, Losso M, Gatell J, Pedersen C, Bogner JR, Lundgren JD, Mocroft A; EuroSIDA Study Group. AIDS. 2011 Jun 19;25(10):1305-15.

A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study.Kowalska JD, Mocroft A, Ledergerber B, Florence E, Ristola M, Begovac J, Sambatakou H, Pedersen C, Lundgren JD, Kirk O; Eurosida Study Group. HIV Clin Trials. 2011 Mar-Apr;12(2):109-17.

Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy.Bannister WP, Cozzi-Lepri A, Kjær J, Clotet B, Lazzarin A, Viard JP, Kronborg G, Duiculescu D, Beniowski M, Machala L, Phillips A; EuroSIDA group. J Antimicrob Chemother. 2011 Apr;66(4):901-11.

A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.Reekie J, Reiss P, Ledergerber B, Sedlacek D, Parczewski M, Gatell J, Katlama C, Fätkenheuer G, Lundgren JD, Mocroft A; EuroSIDA study group. HIV Med. 2011 May;12(5):259-68.

Baker JV, Neuhaus J, Duprez D, Kuller LH, Tracy R, Belloso WH, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon DE, Paton NI, Neaton JD; INSIGHT SMART Study Group. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):36-43.

Dialysis and renal transplantation in HIV-infected patients: a European survey.Trullas JC, Mocroft A, Cofan F, Tourret J, Moreno A, Bagnis CI, Fux CA, Katlama C, Reiss P, Lundgren J, Gatell JM, Kirk O, Miró JM; EuroSIDA Investigators. J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):582-9.   

Serious fatal and nonfatal non-AIDS-defining illnesses in Europe.Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, Gatell J, Rakhmanova A, Johnson M, Kirk O, Lundgren J; EuroSIDA Study Group. J Acquir Immune Defic Syndr. 2010 Oct;55(2):262-70.     

Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies.Reekie J, Kosa C, Engsig F, Monforte Ad, Wiercinska-Drapalo A, Domingo P, Antunes F, Clumeck N, Kirk O, Lundgren JD, Mocroft A; EuroSIDA Study Group. Cancer. 2010 Nov 15;116(22):5306-15.

Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients.Achhra AC, Amin J, Law MG, Emery S, Gerstoft J, Gordin FM, Vjecha MJ, Neaton JD, Cooper DA; INSIGHT ESPRIT & SILCAAT study groups. AIDS. 2010 Jul 31;24(12):1877-86.         

Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD; EuroSIDA Study Group. AIDS. 2010 Jul 17;24(11):1667-78.               

Lower respiratory tract infections among human immunodeficiency virus-exposed, uninfected infants.Mussi-Pinhata MM, Motta F, Freimanis-Hance L, de Souza R, Szyld E, Succi RC, Christie CD, Rolon MJ, Ceriotto M, Read JS; NISDI Perinatal Study Group. Int J Infect Dis. 2010 Sep;14 Suppl 3:e176-82.       

Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites.Belloso WH, Orellana LC, Grinsztejn B, Madero JS, La Rosa A, Veloso VG, Sanchez J, Ismerio Moreira R, Crabtree-Ramirez B, Garcia Messina O, Lasala MB, Peinado J, Losso MH.
HIV Med. 2010 Oct 1;11(9):554-64.         

Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study.Joao EC, Calvet GA, Krauss MR, Freimanis Hance L, Ortiz J, Ivalo SA, Pierre R, Reyes M, Heather Watts D, Read JS; NISDI Perinatal Study Group. J Acquir Immune Defic Syndr. 2010 Feb;53(2):176-85.   

Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe.Soriano V, Mocroft A, Peters L, Rockstroh J, Antunes F, Kirkby N, de Wit S, Monforte Ad, Flisiak R, Lundgren J; EuroSIDA. J Antimicrob Chemother. 2010 Mar;65(3):548-55.  

High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome.Worm SW, Friis-Møller N, Bruyand M, D’Arminio Monforte A, Rickenbach M, Reiss P, El-Sadr W, Phillips A, Lundgren J, Sabin C; D:A:D study group. AIDS. 2010 Jan 28;24(3):427-35.        

Lifson AR, INSIGHT Endpoint Review Committee Writing Group, Belloso WH, Davey RT, Duprez D, Gatell JM, Hoy JF, Krum EA, Nelson R, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson JH, Worley J, INSIGHT Study Group. Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials. HIV Clin Trials. 2010 Jul-Aug;11(4):205-19.

Puls RL, Srasuebkul P, Petoumenos K, Boesecke C, Duncombe C, Belloso WH, Molina JM, Li L, Avihingsanon A, Gazzard B, Cooper DA, Emery S; Altair Study Group. E, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis. 2010 Oct 1;51(7):855-64

Belloso WH, Redal MA. Pharmacogenomics and the path towards personalized medicine. Medicina (Buenos Aires), 2010; 70(3):265-74

Belloso WH, Orellana LC, Grinsztejn B, Madero JS, La Rosa A, Veloso VG, Sanchez J, Ismerio Moreira R, Crabtree-Ramirez B, Garcia Messina O, Lasala MB, Peinado J, Losso MH. Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites HIV Med. 2010 Mar 21.

Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina.Podlekareva DN, Mocroft A, Post FA, Riekstina V, Miro JM, Furrer H, Bruyand M, Panteleev AM, Rakhmanova AG, Girardi E, Losso MH, Toibaro JJ, Caylá J, Miller RF, Obel N, Skrahina A, Chentsova N, Lundgren JD, Kirk O; HIV/TB Study Writing Group.
AIDS. 2009 Nov 27;23(18):2485-95.         

Benefits and burdens of participation in a longitudinal clinical trial.Lazovski J, Losso M, Krohmal B, Emanuel EJ, Grady C, Wendler D. J Empir Res Hum Res Ethics. 2009 Sep;4(3):89-97.              

Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group. J Infect Dis. 2009 Sep 15;200(6):973-83.   

Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.Cozzi-Lepri A, Phillips AN, Martinez-Picado J, Monforte Ad, Katlama C, Eg Hansen AB, Horban A, Bruun J, Clotet B, Lundgren JD; EuroSIDA Study Group. J Infect Dis. 2009 Sep 1;200(5):687-97.  

Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression.Peters L, Mocroft A, Soriano V, Rockstroh JK, Losso M, Valerio L, Aldins P, Reiss P, Ledergerber B, Lundgren JD; EuroSIDA Study Group.
J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):457-63.

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d’Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Clin Infect Dis. 2009 Apr 15;48(8):1138-51.           

Interruption of antiretroviral therapy is associated with increased plasma cystatin C.Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group. AIDS. 2009 Jan 2;23(1):71-82.

INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009 Oct 15;361(16):1548-59

Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis. 2009 Sep 15;200(6):973-83.

Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?Antiretroviral Therapy Cohort Collaboration (ART-CC), Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Günthard HF, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D’Arminio Monforte A, Lampe F, Miró JM, Staszewski S, Sterne JA. AIDS. 2008 Nov 30;22(18):2481-92.          

Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?Reekie J, Mocroft A, Sambatakou H, Machala L, Chiesi A, van Lunzen J, Clumeck N, Kirk O, Gazzard B, Lundgren JD; EuroSIDA Study Group. AIDS. 2008 Nov 12;22(17):2381-90.     

The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe–a review of published results.Podlekareva D, Bannister W, Mocroft A, Abrosimova L, Karpov I, Lundgren JD, Kirk O; EuroSIDA Study Group. Cent Eur J Public Health. 2008 Sep;16(3):99-105. Review.

Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe.Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, Peters L, Karlsson A, Katlama C, Toro C, Kupfer B, Vogel M, Lundgren J; EuroSIDA Study Group. J Infect Dis. 2008 Nov 1;198(9):1337-44.           

Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART.Podlekareva D, Mocroft A, Kirk O, Reiss P, Aldins P, Katlama C, Kovari H, Stellbrink HJ, D’Arminio Monforte A, Lundgren JD; Eurosida Study Group. Scand J Infect Dis. 2008;40(11-12):908-13.    

Determination of the underlying cause of death in three multicenter international HIV clinical trials.Lifson AR; INSIGHT Cause of Death Writing Group, Belloso WH, Carey C, Davey RT, Duprez D, El-Sadr WM, Gatell JM, Gey DC, Hoy JF, Krum EA, Nelson R, Nixon DE, Paton N, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson J, Worley J.
HIV Clin Trials. 2008 May-Jun;9(3):177-85.           

Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study.Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, Reiss P, von Wyl V, Lazzarin A, Katlama C, Phillips AN, Ruiz L, Lundgren JD; EuroSIDA study group. J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):324-33.               

Antiretroviral resistance among HIV type 1-infected women first exposed to antiretrovirals during pregnancy: plasma versus PBMCs.Soto-Ramirez LE, Rodriguez-Diaz R, Durán AS, Losso MH, Salomón H, Gómez-Carrillo M, Pampuro S, Harris DR, Duarte G, De Souza RS, Read JS; NISDI Perinatal Study Group. AIDS Res Hum Retroviruses. 2008 Jun;24(6):797-804.              
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN. J Infect Dis. 2008 Apr 15;197(8):1145-55.     

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R. J Infect Dis. 2008 Apr 15;197(8):1133-44.

Loss to follow-up in an international, multicentre observational study.Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, Vetter N, Dabis F, Gatell J, Lundgren JD; EuroSIDA study group. HIV Med. 2008 May;9(5):261-9.               

Laboratory abnormalities among HIV-1-infected pregnant women receiving antiretrovirals in Latin America and the Caribbean.Ceriotto M, Harris DR, Duarte G, Gonin R, Aguiar RP, Warley EM, Madi JM, Zala CA, Read JS; NICHD International Site Development Initiative (NISDI) Perinatal Study Group. AIDS Patient Care STDS. 2008 Mar;22(3):167-71. No abstract available.

Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J; SMART Study Group. Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS. 2008 Nov 12;22(17):2279-89.

Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, Paton NI, Neaton JD; INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008 Oct 21;5(10):e203.

SMART Study Group, El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med. 2008 Sep 2;149(5):289-99

Lifson AR; INSIGHT Cause of Death Writing Group, Belloso WH, Carey C, Davey RT, Duprez D, El-Sadr WM, Gatell JM, Gey DC, Hoy JF, Krum EA, Nelson R, Nixon DE, Paton N, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson J, Worley J. Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials. 2008 May-Jun;9(3):177-85.

Phillips AN, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman WJ, Williams I, Drummond F, Duprez D, Belloso WH, Goebel FD, Grund B, Hatzakis A, Vera J, Lundgren JD. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther. 2008;13(2):177-87.

SMART CVD Working Group: Phillips AN, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman W, Williams I, Drummond F, Duprez D, Belloso WH, Goebel FD, Grund B, Hatzakis A, Vera J, Lundgren JD. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: findings from the SMART trial. Antiviral Therapy 2008 (in press).

Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2.ESPRIT Research Group, Fox Z, Antunes F, Davey R, Gazzard B, Klimas N, Labriola A, Losso M, Neaton JD, Phillips AN, Ruxrungtham K, Staszewski S, Weiss L, Lundgren JD. HIV Med. 2007 Mar;8(2):112-23.

Infectious disease morbidity among young HIV-1-exposed but uninfected infants in Latin American and Caribbean countries: the National Institute of Child Health and Human Development International Site Development Initiative Perinatal Study.Mussi-Pinhata MM, Freimanis L, Yamamoto AY, Korelitz J, Pinto JA, Cruz ML, Losso MH, Read JS; National Institute of Child Health and Human Development International Site Development Initiative Perinatal Study Group. Pediatrics. 2007 Mar;119(3):e694-704. Epub 2007 Feb 12.

When should antiretroviral therapy for HIV be started?Phillips AN, Gazzard BG, Clumeck N, Losso MH, Lundgren JD. BMJ. 2007 Jan 13;334(7584):76-8. Review. No abstract available.

Analysis of HIV type 1 diversity in pregnant women from four Latin American and Caribbean countries.Gomez-Carrillo M, Pampuro S, Duran A, Losso M, Harris DR, Read JS, Duarte G, De Souza R, Soto-Ramirez L, Salomón H; NISDI Perinatal Study Group. AIDS Res Hum Retroviruses. 2006 Nov;22(11):1186-91.

Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis.Duran AS, Losso MH, Salomón H, Harris DR, Pampuro S, Soto-Ramirez LE, Duarte G, de Souza RS, Read JS; NISDI Perinatal Study Group. AIDS. 2007 Jan 11;21(2):199-205.

Prevention of mother to child HIV transmission.Duran AS, Ivalo SA, Hakim A, Masciottra FM, Zlatkes R, Adissi L, Neaton JD, Losso MH. Medicina (B Aires). 2006;66(1):24-30.

Lifson AR, Rhame FS, Belloso WH, Dragsted UB, El-Sadr WM, Gatell JM, Hoy JF, Krum EA, Nelson R, Pedersen C, Pett SL, Davey RT Jr. Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials. HIV Clinical Trials 2006 May-Jun; 7(3): 125-41.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006 Nov 30;355(22):2283-96.

Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J; EuroSIDA Study Group. J Infect Dis. 2005 Sep 15;192(6):992-1002. Epub 2005 Aug 11.

CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies.Arduino RC, Nannini EC, Rodriguez-Barradas M, Schrader S, Losso M, Ruxrungtham K, Allende MC, Emery S, Fosdick L, Neaton J, Tavel JA, Davey RT, Lane HC; Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT) Vanguard Group; ESPRIT Executive Committee. Clin Infect Dis. 2004 Jul 1;39(1):115-22. Epub 2004 Jun 14.

Losso MH, Belloso WH, Emery S, Benetucci JA, Cahn PE, Lasala MC, Lopardo G, Salomon H, Saracco M, Nelson E, Law MG, Davey RT, Allende MC, Lane HC. A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3. J Infect Dis 2000 May, 181(5): 1614-21.